Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
681-700 of 936 trials

Liver Transplant: QEL-001 Treatment Study

We are testing a new CAR T cell therapy for patients who received an HLA-A2 mismatched liver transplant. The goal is to evaluate its safety and how well it works in this specific group.

Liver Transplant Rejection3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementHepatologyInternal Medicine

Gastroparesis: Naronapride Study

We are evaluating a new medication for people with moderate gastroparesis to see how it works and its safety compared to healthy individuals. This study aims to improve treatment options for those affected by this condition.

GastroparesisSafety phase (I)Gastroenterology

Glioblastoma Multiforme: Long-Term Safety of Temferon

We are monitoring the long-term safety and effects of Temferon in patients who have been treated for glioblastoma multiforme. This study aims to understand any potential side effects and how the disease may progress.

Glioblastoma MultiformeSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesPartially RemoteNeurologyOncology

Pancreatic Cancer: Sotorasib with Chemotherapy

We are studying the safety of combining sotorasib with standard chemotherapy for patients with advanced pancreatic cancer that has a specific genetic mutation. This trial aims to see if this combination improves treatment outcomes.

Pancreatic Cancer≤3 monthsSafety phase (I)No PlaceboStandard MedicinesGastroenterologyOncology

B-Cell Malignancies: BGB-16673 Treatment Study

We are investigating the safety and effectiveness of BGB-16673 combined with other treatments for patients with relapsed or refractory B-cell malignancies. This study aims to find the best dose and assess how well the treatment works.

Relapsed or Refractory B-Cell Malignancies>2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteOncology

Ulcerative Colitis: Vixarelimab Study

We are testing Vixarelimab to see if it is safe and effective for people with moderate to severe active ulcerative colitis. This study aims to improve treatment options for this condition.

Ulcerative Colitis1-2 yearsSafety phase (I)GastroenterologyInternal Medicine

Liver Cirrhosis: RTX001 Macrophage Therapy

We are studying a new treatment using RTX001 autologous macrophages for people with decompensated liver cirrhosis. The trial aims to evaluate its safety and effectiveness in improving liver function.

Liver Cirrhosis>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteHepatologyInternal Medicine

Cancer Treatment: Decitabine and Cedazuridine

We are studying how safe and effective a combination of Decitabine and Cedazuridine is for cancer patients with kidney problems. This research aims to improve treatment options for those affected.

Acute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Solid Tumors>2 yearsSafety phase (I)NephrologyOncology

KIN-2787: New Oral Drug for Cancer

We are studying the safety and effects of KIN-2787 in patients with BRAF and/or NRAS mutation-positive solid tumors. This research aims to find out how well this new treatment works.

Tumors with BRAF and NRAS Mutations>2 yearsSafety phase (I)Oncology

HER2 Positive Metastatic Breast Cancer: ES2B-C001 Study

We are assessing the safety of a new treatment called ES2B-C001, with or without Montanide, for patients with HER2 expressing metastatic breast cancer. This trial aims to understand how safe this new approach is for patients.

HER2 Positive Breast Cancer1-2 yearsSafety phase (I)Oncology

Chronic Lymphocytic Leukemia: CAP-100 Treatment

We are testing a new treatment called CAP-100 for patients with relapsed or refractory chronic lymphocytic leukemia. The study aims to assess how safe and tolerable this treatment is.

B-cell Chronic Lymphocytic LeukemiaSafety phase (I)HematologyOncology

Genital Herpes: IM-250 Treatment Study

We are investigating a new medication, IM-250, for people with recurrent genital herpes to see if it can help reduce outbreaks. The study will also look at the safety of this treatment when given weekly.

Genital Herpes≤3 monthsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesCost ReimbursementDermatologyInfectious Diseases

Lyell Syndrome: Mesenchymal Stromal Cells Treatment

We are testing a new treatment using mesenchymal stromal cells for patients with Lyell syndrome. The study aims to see if this treatment can help improve skin healing and overall health.

Lyell Syndrome>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesDermatologyHematology

Kidney Cancer: New Combination Therapies

We are studying new treatment combinations for people with recurrent kidney cancer after anti-PD-(L)1 therapy. The goal is to evaluate their safety and effectiveness in improving patient responses.

Clear Cell Renal Cell Carcinoma>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesOncology

Advanced Solid Tumors: LY3962673 Treatment

We are studying a new treatment called LY3962673 for people with advanced solid tumors. The goal is to understand its safety and how well it works compared to existing options.

KRAS G12D-mutant Solid Tumors>2 yearsSafety phase (I)Oncology

GA2 Sporozoites with Adjuvants: Immune Response Study

We are exploring whether combining GA2 sporozoites with adjuvants can improve immune responses. This study aims to understand its potential benefits for participants.

Falciparum MalariaSafety phase (I)Infectious Diseases

Rheumatoid Arthritis: GS-0151 Treatment Study

We are investigating a new medication, GS-0151, for people with rheumatoid arthritis. The goal is to see how it may help manage symptoms and improve quality of life.

Rheumatoid Arthritis1-2 yearsSafety phase (I)Internal MedicineRheumatology

Metastatic Colorectal Cancer: JNJ-89402638 Study

We are testing a new drug, JNJ-89402638, for patients with metastatic colorectal cancer. This study aims to evaluate its safety and how it may help in treating this advanced stage of cancer.

Metastatic Colorectal Cancer>2 yearsSafety phase (I)Oncology

Erlotinib Distribution Study

We are exploring how drug transporters affect the distribution of erlotinib in the brain and other organs in humans. This research may help improve treatment strategies for patients using this medication.

Cancer>2 yearsSafety phase (I)Oncology

Clofarabine for Advanced Urothelial Carcinoma

We are studying the safety and effectiveness of Clofarabine in patients with locally advanced or metastatic urothelial carcinoma. The trial aims to find the highest dose that can be tolerated while assessing how well the treatment works.

Bladder Cancer3-6 monthsSafety phase (I)Efficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesOncology